Frank Rimerman Advisors’s AstraZeneca AZN Stock Holding History

Frank Rimerman Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.49M	Buy	12,644 +60	+0.5%	+$11.6K	0.16%	103
2025 Q4	$2.31M	Buy	12,584 +299	+2%	+$52.4K	0.15%	114
2025 Q3	$1.89M	Buy	12,285 +1,945	+19%	+$294K	0.12%	130
2025 Q2	$1.45M	Buy	10,340 +5,413	+110%	+$759K	0.1%	156
2025 Q1	$724K	Sell	4,927 -1,447	-23%	-$209K	0.06%	246
2024 Q4	$835K	Buy	6,374 +1,496	+31%	+$209K	0.06%	221
2024 Q3	$760K	Sell	4,878 -19	-0.4%	-$3.07K	0.05%	261
2024 Q2	$764K	Buy	4,897 +4,878	+25,674%	+$734K	0.05%	263
2024 Q1	$2.58K	Buy	19 +5	+36%	+$662	﹤0.01%	264
2023 Q4	$1.89K	Buy	+14	New	+$1.82K	﹤0.01%	269

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Frank Rimerman Advisors's AZN Position: Q1 2026 in Review

Frank Rimerman Advisors increased its AstraZeneca (AZN) stake by 0.48% in Q1 2026, buying an estimated $11.6K and bringing the position to 12,644 shares worth $2.49M. The position accounts for 0.16% of the portfolio, ranked #103.

Frank Rimerman Advisors first reported a position in AZN in Q4 2023 and has held it in 10 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Frank Rimerman Advisors held 12,644 shares of AstraZeneca worth $2.49M as of Q1 2026.
Frank Rimerman Advisors bought 60 AstraZeneca shares in Q1 2026, an estimated $11.6K.
AstraZeneca made up 0.16% of Frank Rimerman Advisors's portfolio in Q1 2026, its #103 holding.
Frank Rimerman Advisors first reported a position in AstraZeneca in Q4 2023 and has held it in 10 quarters since.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Frank Rimerman Advisors's 13F filing for Q1 2026, filed 29 Apr 2026.